Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma - Trial NCT06364826
Access comprehensive clinical trial information for NCT06364826 through Pure Global AI's free database. This Phase 2 trial is sponsored by Zhejiang Cancer Hospital and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 60 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Zhejiang Cancer Hospital
Timeline & Enrollment
Phase 2
Apr 22, 2024
Apr 22, 2026
Primary Outcome
3-year Event-free survival rate
Summary
This is a prospective, single-center, single-arm, phase II clinical study. The study was
 intended to include patients with locoregionally advanced nasopharyngeal cancer identified by
 histology or cytology, who signed informed consent and met the screening criteria to enter
 the study. Patients will receive induction therapy (sintilimab + bevacizumab + gemcitabine,
 Q3W, 3 cycles) followed by IMRT+ Sintilimab. Consolidation therapy with sintilimab continued
 after radiotherapy until disease progression, intolerable toxicity, death, or the subject's
 decision to withdraw from the study, with a total treatment period of no more than 12 cycles.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06364826
Non-Device Trial